ArticleOncotarget2017

Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency.

Joseph Dosch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.